中文摘要
多发性骨髓瘤(MM)免疫疗法取得的良好结果,凸显了根据免疫组分对患者进行更精细分层的必要性。其中最迫切关注的是细胞毒性淋巴细胞,例如对 MM 监视和治疗不可或缺的自然杀伤(NK)细胞。
我们对 10 例 MM 患者和 10 名年龄、性别匹配健康供者的 NK 细胞进行单细胞 RNA 测序,发现骨髓(BM)和外周血中的 NK 细胞图谱均出现重要转录变化。MM 患者成熟细胞毒性 CD56dim NK 亚群比例降低,后期 NK 亚群相对增多;后者表达 NF-κB 和 I 型干扰素炎症特征。MM 患者中积聚的这类 NK 亚群 CD16 和 CD226 表达较低,细胞毒功能较差。MM 患者 CD16/CD226低表达 NK 细胞还存在黏附缺陷,表现为淋巴细胞功能相关抗原 1(LFA-1)整合素活化和肌动蛋白聚合减少,这可能解释其体外效应功能有限。
最后,对 Intergroupe Francophone du Myélome(IFM)2009 试验中 177 例 MM 患者的回顾性队列骨髓浸润 NK 细胞进行分析,结果显示 NK 细胞比例较高且 CD16 和 CD226 表达较低与总生存期较短相关。
因此,随着 MM 进展,效应功能降低的 CD16/CD226低表达 NK 细胞逐渐积累,并对患者临床结局产生负面影响。鉴于利用 NK 细胞治疗骨髓瘤受到日益关注,深入了解 MM 相关 NK 细胞功能障碍将推动开发更有效的 MM 免疫治疗药物。
展开英文摘要原文
The promising results obtained with immunotherapeutic approaches for multiple myeloma (MM) call for a better stratification of patients based on immune components. The most pressing being cytotoxic lymphocytes such as natural killer (NK) cells that are mandatory for MM surveillance and therapy.
Here, we performed a single-cell RNA sequencing analysis of NK cells from 10 patients with MM and 10 age/sex-matched healthy donors that revealed important transcriptomic changes in the NK cell landscape affecting both the bone marrow (BM) and peripheral blood compartment. The frequency of mature cytotoxic CD56dim NK cell subsets was reduced in patients with MM at the advantage of late-stage NK cell subsets expressing NF- B and interferon-I inflammatory signatures.
These NK cell subsets accumulating in patients with MM were characterized by low CD16 and CD226 expression and poor cytotoxic functions. MM CD16/CD226Lo NK cells also had adhesion defects with reduced lymphocyte function-associated antigen 1 (LFA-1) integrin activation and actin polymerization that may account for their limited effector functions in vitro.
Finally, analysis of BM-infiltrating NK cells in a retrospective cohort of 177 patients with MM from the Intergroupe Francophone du My lome (IFM) 2009 trial demonstrated that a high frequency of NK cells and their low CD16 and CD226 expression were associated with a shorter overall survival.
Thus, CD16/CD226Lo NK cells with reduced effector functions accumulate along MM development and negatively affect patients' clinical outcomes. Given the growing interest in harnessing NK cells to treat myeloma, this improved knowledge around MM-associated NK cell dysfunction will stimulate the development of more efficient immunotherapeutic drugs against MM.
论文信息
- 作者
- Blanquart E、Ekren R、Rigaud B、Joubert MV、Baylot V、Daunes H、Cuisinier M、Villard M
- 单位
- Cancer Research Center of Toulouse, INSERM, Centre National de la Recherche Scientifique, Université Toulouse III-Paul Sabatier, Toulouse, France.France
- 文献类型
- 非美国政府资助研究
- 期刊
- Blood2024 Sep 19